Enbrel Related Published Studies
Well-designed clinical trials related to Enbrel (Etanercept)
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. [2008.10]
Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. [2008.10]
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. [2008.08.02]
Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. [2008.08]
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. [2008.07]
The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. [2008.07]
Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. [2008.07]
Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. [2008.06]
Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. [2008.05]
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. [2008.05]
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. [2008.05]
Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. [2008.04]
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. [2008.03]
Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. [2008.03]
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. [2008.02]
Etanercept treatment for children and adolescents with plaque psoriasis. [2008.01.17]
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. [2007.12]
Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. [2007.12]
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]
Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. [2007.11]
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. [2007.09.15]
The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy. [2007.08.27]
A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. [2007.07]
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. [2007.07]
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. [2007.07]
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. [2007.06]
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. [2007.06]
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. [2007.04]
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. [2007.02]
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. [2007.01]
Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. [2007]
Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. [2006.12]
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. [2006.12]
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. [2006.12]
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. [2006.11]
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. [2006.10]
Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. [2006.10]
A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. [2006.09]
Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig. [2006.09]
Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. [2006.06]
Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections. [2006.06]
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. [2006.05]
Effects of etanercept in patients with the metabolic syndrome. [2006.04.24]
Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. [2006.04.15]
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. [2006.04]
The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. [2006.04]
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. [2006.04]
Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. [2006.04]
Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. [2006.03]
Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. [2006.03]
Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. [2006.03]
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. [2006.02]
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. [2006.01.07]
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. [2006.01]
Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). [2006.01]
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. [2006]
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. [2005.12]
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. [2005.11]
Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. [2005.11]
Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. [2005.10]
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. [2005.09]
Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. [2005.09]
Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. [2005.08.15]
Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. [2005.08]
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. [2005.08]
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. [2005.07]
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). [2005.07]
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. [2005.06]
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. [2005.04]
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. [2005.03]
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. [2005.03]
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. [2005.02.15]
Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. [2005.01]
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. [2004.12]
Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. [2004.11]
The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. [2004.09]
A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. [2004.08]
Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. [2004.08]
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. [2004.07]
Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. [2004.07]
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. [2004.07]
Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. [2004.05]
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. [2004.05]
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). [2004.04.06]
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. [2004.02.28]
Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. [2004.02.15]
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. [2004.02]
Etanercept: in ankylosing spondylitis. [2004]
A randomized trial of etanercept as monotherapy for psoriasis. [2003.12]
Etanercept as monotherapy in patients with psoriasis. [2003.11.20]
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. [2003.11]
Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. [2003.11]
Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. [2003.08]
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. [2003.06]
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. [2003.06]
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. [2003.06]
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. [2003.04]
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. [2003.04]
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. [2003.04]
Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. [2003.01]
Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. [2002.11]
|
